Share This

Public company info - Jinxin Fertility Group Limited , 01951.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Jinxin Fertility Group Limited, 01951.HK - Company Profile
Chairman Zhong Yong
Share Issued (share) 2,508,000,000
Par Currency U.S. Dollar
Par Value 1.0E-5
Industry Medical Equipment & Services
Corporate Profile Business Summary: The Group is principally engaged in the provision of (i) assisted reproductive services; (ii) management services; (iii) ambulatory surgery centre facilities services; and (iv) ancillary medical services. Performance for the year: Revenue of the Group for the year ended December 31, 2019 was approximately RMB1,648.5 million, representing an increase of 78.8% when compared with that of approximately RMB922.0 million for the year ended December 31, 2018. Gross profit of the Group for the year ended December 31, 2019 was approximately RMB816.8 million, representing an increase of 97.7% when compared with that of approximately RMB413.1 million for the year ended December 31, 2018. Net profit of the Group for the year ended December 31, 2019 was approximately RMB420.7 million, representing an increase of 98.3% when compared with that of approximately RMB212.1 million for the year ended December 31, 2018. Business Review During the Reporting Period, the Group continued to adhere to the Group’s strategy of establishing a leading global ARS platform with integrated abilities, aiming to address increasing unmet demand, in particular from Chinese patients. The Group have built a strong market reputation stemming from superior success rates, experienced medical staff and high quality patient care that have greatly contributed to the Group’s role as a leading ARS provider in China and the United States. With this strategy and reputation in mind, the Group continued to expand the Group’s network operations, enhanced patient experience and loyalty, improved brand awareness through marketing and cooperation initiatives, recruited talents to the Group’s experienced network of physicians and expanded service offerings across the Group’s network of operations. The Reporting Period was also highlighted by the listing of the Group’s shares on the Stock Exchange on June 25, 2019. Prospects: The global ARS market has increased over the years and such growth is expected to continue over the next few years, particularly due to an increased prevalence of infertility, caused by lifestyle changes, increase in the average age of the first birth, and increased public awareness on birth defects and prevention. Compared with Japan, Europe and the United States, the market penetration of ARS in China is still low. With improved awareness and increasing disposable income, patients in China will continue to seek more sophisticated IVF treatment, including receiving IVF treatment abroad. As a leading ARS provider in China and the United States, the Group have established a competitive advantage on branding, technology, medical staff and management in a market with significant entry barriers. According to the market research report on China and the United States ARS markets prepared by Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., in terms of IVF treatment cycles and revenue generated from ARS institutions in 2018, the Group’s network in China ranked third among all ARS institutions in China. Due to an increase in the number of people seeking more ARS options, 18,000 patients in China went overseas for ARS, of which 30% (5,400 patients) went to the United States. The number of patients from China going to the United States for ARS is expected to grow to 13,500 by 2023. The Group’s network in the United States is well-positioned to benefit from this future growth. In 2017, HRC Fertility ranked first among all ARS providers in the United States, in terms of IVF treatment cycles provided to ARS patients traveling from China to the United States for treatment. In 2018, HRC Fertility also ranked first in the Western United States in terms of both revenue generated from ARS clinics and IVF treatment cycles performed. In terms of success rates of IVF treatment cycles, a metric that ARS providers primarily compete on, the Group have a competitive advantage with success rates well above the national average in both China and the United States ARS markets. In 2018, the average success rate of an IVF treatment cycle in China was approximately 45% compared to the Group’s network in China of 54%. Similarly, in the United States ARS market, the average success rate in 2016 was 52.5% compared to the Group’s network in the United States of 62%. In view of the aforesaid, the Group intend to leverage the Group’s position as a leading ARS provider and favorable industry prospects by continuing to pursue the following core strategies that have contributed to the Group’s success so far. Increased market share, productivity and capacity Continue to improve the Group’s brand awareness Continue to invest in research and development to enhance overall performance Expand the Group’s platform reach through acquisitions Minimize the impact of the outbreak of Novel Coronavirus

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.